https://www.selleckchem.com/products/og-l002.html
, and downregulation of cytokine storm, with no adverse effects attributable to the treatment. Given these outcomes, it may be possible to use this type of treatment for serious inflammatory lung disease with a mechanism similar to COVID-19 in the future. However, it is necessary to evaluate the safety and efficacy of MenSCs-derived secretome therapy in clinical trials on a larger population of patients. ClinicalTrials.gov Identifier NCT05019287. Registered 24AGUEST 2021, retrospectively registered, https//clinicaltrials.gov/ct2/show/re
Like
Comment
Share
